Financial analysts are predicting the number of patients using Tysabri will fall far below Biogen Idec Inc.'s forecast, following the Cambridge biotech company's disclosure last week that two more patients using the multiple sclerosis drug contracted a potentially fatal brain disease. In an investor note yesterday, Deutsche Bank analyst Mark Schoenebaum said even under his best scenario, Tysabri will only have about 75,000 users by 2013, far short of the company's goal of 100,000 by 2010. In a more conservative scenario, Schoenebaum predicts just 56,000 patients will use the drug by 2013. And in the worst case, he said, the drug could get pulled from the market if more safety problems emerge.
Massachusetts Drug Treatment